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The role of thyroid hormones (TH) in the normal functioning of adult mammalian brain is unclear. Our studies have identified
synaptosomal Na+-K+-ATPase as a TH-responsive physiological parameter in adult rat cerebral cortex. L-triiodothyronine
(T
3
) and L-thyroxine (T
4
) both inhibited Na+-K+-ATPase activity (but not Mg2+-ATPase activity) in similar dose-dependent
fashions, while other metabolites of TH were less effective. Although both T
3
and the 𝛽-adrenergic agonist isoproterenol inhibited
Na+-K+-ATPase activity in cerebrocortical synaptosomes in similar ways, the 𝛽-adrenergic receptor blocker propranolol did not
counteract the effect of T
3
. Instead, propranolol further inhibited Na+-K+-ATPase activity in a dose-dependent manner, suggesting
that the effect of T
3
on synaptosomal Na+-K+-ATPase activity was independent of 𝛽-adrenergic receptor activation. The effect of
T
3
on synaptosomal Na+-K+-ATPase activity was inhibited by the 𝛼
2
-adrenergic agonist clonidine and by glutamate. Notably, both
clonidine and glutamate activate Gi-proteins of the membrane second messenger system, suggesting a potential mechanism for
the inhibition of the effects of TH. In this paper, we provide support for a nongenomic mechanism of action of TH in a neuronal
membrane-related energy-linked process for signal transduction in the adult condition.
1. Introduction
Thyroid hormones (TH) exertmajor influences on the growth
and development of the mammalian brain through specific
nuclear receptor-mediated gene expression. Although several
different isoforms of nuclear receptors for TH have been
described in adult mammalian brain, their physiological
function is quite unclear [1–4]. Still, adult onset of dysthy-
roidism develops a number of functional, neurological and
psychological manifestations in humans [5–7]. In contrast
to the developing brain, most of the changes resulting from
hormone variations in the adult condition are reversible with
the proper adjustment of circulatory TH [5–7].
Recent evidence has demonstrated that L-triiodothyro-
nine (T
3
) is distributed, concentrated, andmetabolized in the
synaptosomal fraction of adult rat cerebral cortex [5, 8, 9].
Specific T
3
-binding sites have also been described in cere-
brocortical synaptosomes [10, 11] and a graded binding
of T
3
to its synaptosomal receptor binding sites has been
correlated with the corresponding inhibition of the Na+-K+-
ATPase activities in adult rat brain [11]. TH rapidly alters in
vitro phosphorylation of synaptosomal proteins in a dose-
dependent fashion [12]. TH levels are also altered in adult
rat brain in different thyroid conditions [9]. TH enhances
calcium entry in adult rat brain synaptosomes [13–15], in
hypothyroidmouse brain [16], and in single ratmyocytes [17].
However, there is a lack of clear understanding of the
mechanism(s) of action of TH in the regulation of synaptic
functions in adult neurons. The present study investigates
the pathways of T
3
-mediated signaling from its binding to
the synaptosomal membrane receptors to the subsequent
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activation of second messenger system components that ulti-
mately affect the further downstream effector molecule, the
Na+-K+-ATPase. In this paper, we hypothesize a nongenomic
mechanism of action of TH in neuronal membrane-related
energy-linked process(es) for signal transduction in adult
condition.We have used 𝛼- and 𝛽-adrenoceptor agonists and
antagonists for modulation of the activity of Gs- and Gi-
proteins of the membrane adenylate cyclase system. Portions
of this work have appeared elsewhere in a preliminary form
[18, 19].
2. Materials and Methods
2.1. Materials. The following compounds were purchased
from Sigma Chemical Company, USA: bovine serum albu-
min (BSA), clonidine hydrochloride (CLO), disodium-ATP,
isoproterenol hydrochloride (ISO), 2-mercaptoethanol, oua-
bain octahydrate, prazosin hydrochloride (PRA), phenyl-
ephrine hydrochloride (PHE), propranolol hydrochloride













hydrochloride (YOH), dibutyryl 3󸀠,5󸀠-cyclic adenosine mon-
ophosphate sodium salt (DB cAMP), and sodium orthova-
nadate.
2.2. Treatment of Animals. Adult male Charles Foster rats (3
months old) were housed at 25 ± 1∘C in 12 h dark-12 h light
conditions and fed ad libitumwith standard rat diet andwater.
The animals were sacrificed by quick decapitation and the
brains were removed into ice-cold 250mM sucrose solution.
The cerebral cortices were dissected out for synaptosomal
fraction preparation.
2.3. Preparation of Synaptosomes. The synaptosomes from
thecerebral cortex were prepared as described previously
[20]. Briefly, the cerebral cortex was homogenized (10%
weight/volume) in 0.32M sucrose and centrifuged at
1000 g for 10 minutes to remove cell debris and nuclei. The
supernatant was collected and recentrifuged at 1000 g for
another 10min. The resulting pellet was discarded and the
supernatant was layered over 1.2M sucrose and centrifuged
at 34,000 g for 50min at 4∘C. The fraction collected between
the 0.32M and 1.2M sucrose layer was diluted at 1 : 1.5 with
ice-cold bidistilled water, further layered on 0.8M sucrose,
and again centrifuged at 34,000 g for 30min. The pellet thus
obtained was washed and repelleted at 20,000 g for 20min.
Synaptosomal pellets were lysed by suspending in ice-cold
bidistilled water to release the occluded Na+-K+-ATPase
activity.
2.4. Assay of Synaptosomal Na+-K+-ATPase Activity. Synap-
tosomal Na+-K+-ATPase activity was assayed as ouabain-
sensitive ATP hydrolysis in reaction mixtures of (i) 30mM
imidazole-HCl, 130mMNaCl, 20mMKCl, and 4mMMgCl
2
and (ii) 30mM imidazole-HCl, 4mM MgCl
2
, and 1mM
ouabain, at pH 7.4. Both the reaction media (i) and (ii)
were first preincubated in vitro with or without simultaneous





) and TH-analogue (T
2
) (0.001 nM to 1 𝜇M), adrenergic
drugs (1 nM for ISO, PRA, PHE and YOH; 1 nM–100 nM
for CLO and PROP), glutamate (100𝜇M), DB cAMP (1 𝜇M–
5mM), and sodium orthovanadate (10 nM–2mM) followed
by addition of the synaptosomal lysates, each containing
20–50𝜇g synaptosomal protein, at 0∘C for 60 minutes in
dark. To get a steady-state ouabain binding, both the assay
media (i) and (ii), with and without ouabain, respectively, as
described above, were preincubated for 60min at 0∘C in the
dark, followed by a 5-min incubation at 37∘C to equilibrate
the temperature. The reaction was started by adding 4mM
Tris-ATP and incubated at 37∘C for 10min. An aliquot of
100 𝜇L of 10% sodium dodecylsulfate was added to stop the
enzymatic reaction. The inorganic phosphate (Pi ) formed
was determined in the reactionmixture [21]. Na+-K+-ATPase
activity was calculated as difference in the Pi content between
media (i) and (ii) and expressed as 𝜇mols Pi/h/mg protein
[22].The ouabain-sensitive portion of the total ATPase (Na+-
K+-Mg2+-ATPase) was determined from the Pi released in
the medium (i) minus that in medium (ii). The Pi released
from the reaction medium (ii) was used for determination
of the synaptosomal Mg2+-ATPase activity. Synaptosomal
Mg2+-ATPase activity, therefore, was assayed as the ouabain-
insensitive ATP hydrolysis.
2.5. Measurement of Protein. Synaptosomal protein content
wasmeasured using bovine serumalbumin as a standard [23].
2.6. Statistical Analysis. Results are expressed as the mean ±
SEM of 3-4 separate experiments or as mentioned. Each
experiment was made from six rats. The statistical analysis
of the data was performed by Student’s t-test, considering
𝑃 < 0.05 as the significance level. The data for multiple
groups were also analyzed by one-way ANOVA followed by
Student Newman-Keuls post-hoc comparisons using Sigma-
stat software. Nonlinear regression analysis was performed
using GraphPad Prism software.
3. Results
3.1. Effects of T
3
and Metabolites on Na+-K+-ATPase Activity.
In vitro addition of various doses of T
3
to the synaptosomal
fraction (which is devoid of cell nuclei) confirmed our
previous observation [11] and showed nearly the same trend
of a dose-dependent inhibition (IC
50
= 166.4 ± 55.0 pM;
maximal inhibition = 63.2 ± 3.4% at 95% confidence levels)
of Na+-K+-ATPase activity. No significant effect of T
3
was
noticed on the Mg2+-ATPase specific activity (Figure 1). T
4





= 77.2 ± 31.8 pM; maximal inhibition = 66.5 ±
7.2%), while T
2
had minimal effects (Figure 2). Furthermore,
the same range of doses (10−12–10−8M) of r-T
3
did not inhibit
either Na+-K+-ATPase or Mg+2-ATPase activities (data not
shown).
3.2. Effect of T
3
and 𝛽-Adrenergic Agonists/Antagonists on
Na+-K+-ATPase Activity. Equimolar doses (1 nM) of T
3
and






















Figure 1: Inhibitory effect of various doses (0.001 nM–100 nM) of T
3
on synaptosomal Na+-K+-ATPase or Mg2+-ATPase activity, in vitro.
Thedata are represented asmean± SEMof ten separate experiments,
taking six animals in each group. The vertical lines denote SEM.



































on synaptosomalNa+-K+-ATPase activity, in vitro.Thedata are
represented as mean ± SEM of four separate experiments, taking six
animals in each group. The vertical lines denote SEM. Filled circles
indicate effects of T
4
on Na+-K+-ATPase activity while filled squares
indicate effects of T
2
.
the nonselective 𝛽-adrenergic agonist ISO were added sepa-
rately in vitro, inhibited the Na+-K+-ATPase enzyme activity
by 41.3% and 42.6%, respectively (Figure 3).The nonselective
𝛽-adrenergic antagonist PROP alone did not alter the enzyme
activity at different doses (1 nM, 10 nM, and 100 nM). The
inhibitory action of ISO (1 nM) on the Na+-K+-ATPase activ-
ity was counteracted by PROP (1 nM), whereas PROP could
not block T
3
-mediated inhibition of the enzyme activity.
Instead PROP potentiated the T
3
-mediated inhibition of the









































































































Figure 3: Effect of T
3
on synaptosomal Na+-K+-ATPase activity and
its modulation by a 𝛽-adrenergic receptor agonist (ISO) and a 𝛽-
adrenergic receptor antagonist (PROP) in vitro. A half-maximally
effective dose of T
3
(1 nM)was chosen from the dose-response curve
for T
3
in Figure 1. The data are represented as mean ± SEM of five
separate experiments taking six animals in each group. a𝑃 < 0.001,
compared to the control group. b𝑃 < 0.001 and c𝑃 < 0.05, compared
to T
3
(1 nM) + PROP (100 nM) group (one-way ANOVA followed by
Newman-Keuls test). The vertical lines denote SEM.
differences in the potentiation of theT
3
effect (1 nM) byPROP
on Na+-K+-ATPase activity were noticed between 1 nM and
100 nM (𝑃 < 0.001) and between 10 nM and 100 nM (𝑃 <
0.05) doses (Figure 3).
3.3. Effects of T
3
and 𝛼-Adrenergic Agonists/Antagonists on
Na+-K+-ATPase Activity. The effects of in vitro addition of





-adrenergic receptor antagonist) on synaptoso-
mal Na+-K+-ATPase activity or Mg2+-ATPase activity were
minimal (Figure 4). Furthermore, 1 nM doses of PHE or PRA
did not alter the inhibitory effect of 1 nM T
3
on Na+-K+-
ATPase activity, nor did it change the Mg2+-ATPase activity,
in vitro (Figure 4).
Similarly, in vitro addition of CLO (𝛼
2
-adrenergic ago-
nist) at different doses did not elicit significant changes in the
synaptosomal Na+-K+-ATPase activity (Figure 5). However,
when CLO was added in the presence of an equimolar
dose of T
3
, the inhibitory effect of T
3
on the Na+-K+-
ATPase activity was completely counteracted. The effect of
T
3





: 10.29 ± 0.2 𝜇mols Pi/h/mg protein;































































Figure 4: Modulation of the T
3
action on synaptosomal Na+-K+-ATPase activity by a selective 𝛼
1
-adrenergic agonist (PHE) and a selective
𝛼
1
-antagonist (PRA) in vitro. A half-maximally effective dose of T
3
(1 nM) was chosen from the dose-response curve for T
3
in Figure 1. The
doses for PHE and PRA used for the in vitro experiment were 1 nM in each case. The data are represented as mean ± SEM of five separate
experiments, taking six animals in each group. The vertical lines denote SEM.
Control: 26.22 ± 0.2 𝜇mols Pi/h/mg protein) along with 1 nM
CLO (100 nM T
3
+ 1 nM CLO: 15.23 ± 0.4 𝜇mols Pi/h/mg
protein); however, 1 nM CLO attenuated the effect of T
3
(100 nM) by 32% more towards the control value (data not
shown graphically). The 𝛼
2
-adrenergic receptor antagonist
YOH also inhibited synaptosomal Na+-K+-ATPase activity
(Figure 5). Inhibition of the enzyme activity in the presence
of both 1 nM T
3
and 1 nM YOHwas found to be intermediate
between the levels of inhibition by either compound alone,
although there were no significant differences between these
groups (Figure 5).
3.4. Effect of T
3
and Glutamate on Na+-K+-ATPase Activity.
In vitro addition of 100 𝜇M glutamate alone did not alter
the synaptosomal Na+-K+-ATPase activity compared to con-
trol values, whereas, addition of 100𝜇M glutamate showed
complete attenuation of T
3
(10 nM)-mediated inhibition of
synaptosomal Na+-K+-ATPase activity in adult rat cerebral
cortex (Figure 6). A higher dose of T
3
(10 nM) was chosen, in
order to test the effect of glutamate against a greater inhibitory
action on the Na+-K+-ATPase activity.
3.5. Effect of DB cAMP and T
3
on Na+-K+-ATPase Activity.
To study the effect of DB cAMP on modulation of Na+-K+-
ATPase activity by T
3
, first a dose response experiment with
various concentrations ofDB cAMP (0.001mM to 5mM)was
performed. In vitro addition of DB cAMP showed a typical
sigmoidal curvewith gradual decrease in theNa+-K+-ATPase
activity to a maximal inhibition at 0.2mM (Figure 7(a)).
From this standardization, we chose to use a 0.2mM final
concentration of DB cAMP for further experiments. In vitro
addition of DB cAMP (0.2mM) with and without various
doses of T
3
(0.001 nM–10 nM) was examined for effects on
Na+-K+-ATPase activity (Figure 7(b)). T
3
-induced inhibi-
tion of synaptosomal Na+-K+-ATPase activity was further
depressed in the presence of 0.2mMDB cAMP. However, the
two curves appeared to converge at the highest doses of T
3
.
3.6. Influence of Sodium Orthovanadate on Modulation of
Na+-K+-ATPase Activity by T
3
. The in vitro effect of sodium
orthovanadate, a protein tyrosine phosphatase inhibitor, was
examined in cerebrocortical synaptosomes. The cerebrocor-
tical synaptosomes were treated with a fixed dose of T
3
(10 nM)with or without different doses of sodium o-vanadate
(Figure 8). A higher dose of T
3
(10 nM) was chosen from
the T
3
dose-response curve, considering its greater inhibitory
action on the Na+-K+-ATPase activity. T
3
caused an inhibi-
tion of Na+-K+-ATPase specific activity, and this effect was
enhanced by sodium orthovanadate in a dose-dependent
way. In general, the effects of sodium orthovanadate and T
3
appeared to be additive until the Na+-K+-ATPase specific
activity was completely inhibited.
4. Discussion
The objective of the present investigation was to search for
possible mechanisms for the inhibition by TH of synaptoso-
mal Na+-K+-ATPase activity in adult rat cerebral cortex.
Initial studies examined the specificity of the effect
according to the pattern of iodination of the hormone
derivatives (Figures 1 and 2). In vitro inhibitory effect of T
3
on synaptosomal Na+-K+-ATPase activity supported our
previous observation and showed nearly the same trend
of a dose-dependent inhibition of Na+-K+-ATPase activity
[11]. In addition to our earlier report, the current study
showed an insignificant effect of T
3
on the synaptosomal
Mg2+-ATPase specific activity (Figure 1). In vitro addition of
T
4
also indicated similar pattern of inhibitory influence on
the synaptosomal Na+-K+-ATPase activity, like the effect of
T
3
, with no significant changes on the Mg2+-ATPase activity.
The effects of TH on Na+-K+-ATPase activity seemed to be























































































































Figure 5: Modulation of the T
3
action on synaptosomal Na+-K+-
ATPase activity by an 𝛼
2
-adrenergic agonist (CLO) and an 𝛼
2
-
adrenergic antagonist (YOH) in vitro. The data are represented as
mean ± SEM of six separate experiments taking six animals in each
group. a𝑃 < 0.001, compared to the control group (one-wayANOVA
followed by Newman-Keuls test). The vertical lines denote SEM.





were without activity in the current
studies. T
3
was less potent than T
4
. It is consistent with
reports of the relative affinities of the two compounds for
a cell surface receptor, integrin 𝛼v𝛽3 known to mediate a
variety of nongenomic effects of THs [24].
Binding of T
4
to integrin 𝛼v𝛽3 causes internalization
of the receptor and nongenomically promotes phospho-
rylation of mitogen-activated protein kinase/extracellular
regulated kinase 1 and 2 (MAPK/ERK
1/2
) in the CV-1 line
of monkey fibroblasts [24]. A similar mechanism seems
likely in chick chorioallantoic membrane [25]. Following
the internalization of the integrin 𝛼v𝛽3, the 𝛼v monomer
is translocated to the nucleus, where it may transcription-
ally regulate expression of protein [26]. TH causes lungs
to rapidly (within hours) increase alveolar fluid clearance
[27] and to express increased Na+-K+-ATPase protein by
a MAPK/ERK
1/2
-dependent pathway [28]. Note, however,
that the current finding of an immediate effect to decrease
Na+-K+-ATPase activity could not be due to a mechanism
involving transcriptional regulation, since the synaptosomal
preparation is devoid of cell nuclei. It is also suggested that
someof the effects of T
3
stimulation of the integrin𝛼v𝛽3 could



































































Figure 6: Modulatory effect of glutamate on T
3
-induced inhibition
of synaptosomal Na+-K+-ATPase activity in cerebral cortex, in vitro.
A higher dose of T
3
(10 nM) was chosen from the T
3
dose-response
curve, considering its greater inhibitory action on the Na+-K+-
ATPase activity and to observe the effect of 100 𝜇Mglutamate on this
T
3
-induced inhibition. The data are represented as mean ± SEM of
four separate experiments taking six animals in each group. a𝑃 <
0.001, compared to the control group (one-way ANOVA followed
by Newman-Keuls test).
A potential mechanism for the inhibitory effects of TH
in the present study might be the regulation of phospho-
rylation of Na+-K+-ATPase or a modulatory molecule. It is
well known that catecholamine-mediated phosphorylation
of Na+-K+-ATPase inhibits enzymatic activity in Chinese
hamster ovary (CHO) cells, but not through a process of
internalization of the enzyme [30–32]. Intriguingly in this
respect, one of the proteins found to be phosphorylated at
the tyrosyl residue in synaptosomes treated for 5 s with TH
had a molecular weight of 95 kD [12], matching the size of 𝛼-
subunit of Na+-K+-ATPase [33].
The significant inhibition of the synaptosomal Na+-
K+-ATPase activity in vitro by T
3
confirmed our pre-
vious in vivo observations [22]. In order to character-
ize this inhibitory influence of THs on the synaptosomal
membrane, we intended to study the effect of adrenergic
receptor agonists and antagonists which regulate guanine
nucleotide binding proteins (G-proteins) via their activating
and inhibitory actions. Both T
3
and ISO (𝛽-adrenergic recep-
tor agonist) showed an analogous but independent (parallel)
inhibitory effect on the enzyme activity (Figure 3). ISO-
induced inhibition of Na+-K+-ATPase activity was blocked
by PROP (𝛽-adrenergic receptor blocker) indicating that
the synaptosomal membrane interaction with ISO was likely
6 Journal of Thyroid Research
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Figure 7: Influence of DB cAMP and T
3
on synaptosomal Na+-K+-ATPase activity, in vitro. (a) Inhibitory effect of various doses of DB cAMP
on synaptosomal Na+-K+-ATPase activity, in vitro. The data are represented as mean ± SEM of four separate experiments, taking six animals
in each group.The vertical bars denote SEM. (b) Interaction of the effects of of DB cAMP and T
3
on synaptosomal Na+-K+-ATPase activity, in
vitro. Filled squares indicate effects of graded doses of T
3
(0.001 nM–10 nM) alone on Na+-K+-ATPase activity while filled triangles indicate
effects of the 0.2mM dose of DB cAMP with graded doses of T
3
(0.1 pM–1𝜇M).
a 𝛽-adrenoceptor-mediated event, potentially coupled to Gs-
protein. However, PROP was completely unable to block
T
3
-mediated inhibition of synaptosomal Na+-K+-ATPase
activity. This clearly indicated that T
3
-mediated inhibition
of the enzyme activity was not coupled to 𝛽-adrenoceptor,
but rather, may have had a similar effect through another
kind of receptor. The augmentation of the T
3
effect by PROP
appeared to be a type of synergistic action, the mechanism
of which remains unclear at present. Increased activity of
adenylate cyclase caused by THs, independent of propranolol
blockade, has been shown in cultured cerebral cells from
embryonic mice, suggesting that the effect of T
3
was not
mediated through a 𝛽-adrenergic-dependent system [34].
The T
3
-induced increase in sodium current in neonatal rat
myocytes also could not be blocked by PROP, whereas it
was antagonized by amiodarone, a nonspecific blocker of 𝛽-
adrenoceptor, suggesting that the effects were not mediated
through 𝛽-adrenergic signaling pathways [35]. However, 𝛽-
adrenoceptor blockade by chronic subcutaneous delivery of
PROP for 14 days has been shown to downregulate levels of




-mRNA in mouse heart,
which may influence the genomic effect of the hormone [36].
Next, we wanted to check for the role of an 𝛼
1
-
adrenergic receptor agonist and antagonist. Agonists for
the 𝛼
1
-adrenergic receptor mediate their actions through
Gq protein followed by activation of phospholipase C and
subsequent production of the second messengers inositol
triphosphate anddiacylglycerol, an activator of protein kinase
C [37]. Neither PHE (selective 𝛼
1
agonist) nor PRA (𝛼
1
antagonist) had an influence onNa+-K+-ATPase activity. Fur-
thermore, neither compound interactedwith the effects of T
3
.
Mg2+-ATPase activity remained unaltered when treated with
either of these 𝛼
1
-adrenergic drugs (agonist and antagonist)
and T
3
, alone or in combination (Figure 4). These results
suggest that the effects of T
3
on Na+-K+-ATPase activity do
not share common mechanisms with 𝛼
1
-receptors.
On the other hand, CLO, an 𝛼
2
-adrenergic receptor
agonist (Figure 5), and glutamate (Figure 6), possibly acting
via a metabotropic glutamate receptor (mGluR), blocked
T
3
-induced inhibition of Na+-K+-ATPase activity. Neither
CLO nor glutamate showed any significant effect on the
Na+-K+-ATPase activity in rat hippocampus and frontal
cortex homogenates [38]. One possibility would be that the
counteraction of the effect of T
3
on synaptosomal Na+-K+-
ATPase by CLO and glutamate might be mediated through
the inhibition of adenylate cyclase activity with the activation
of inhibitory G-protein (Gi) followed by the inhibition of
cAMP synthesis and the protein phosphorylation cascade
mechanism. It is well known that 𝛼
2
-adrenergic agonists act
through stimulation of Gi-protein [18, 19, 39, 40].
Association of the glutamate transporter with Na+-
K+-ATPase in synaptosomes has been implicated by their
correlated regulation via protein kinases [41]. Glutamate
also has been reported to inhibit adenylate cyclase activ-
ity in rat hippocampal synaptosomes [39, 40, 42, 43], as
well as in striatal and cerebrocortical neurons, both in
intact cells and membranes [40] via metabotropic glutamate
receptors (mGluRs), which are coupled to effector systems
through GTP binding proteins. In fact, in the nucleus tractus
solitarius of adult brain, it was shown that an antibody
to the Gi inhibited the effects of mGluRs [44]. mGluR1
and mGluR
5
subtypes are coupled to phosphatidyl inos-
itol hydrolysis/Ca2+-signal transduction. mGluR
1
has also
been shown to stimulate release of arachidonic acid and to









subtypes appear to be coupled to inhibition



































Figure 8: Modulation of the T
3
action on synaptosomal Na+-K+-
ATPase activity by sodium orthovanadate. A higher dose of T
3
(10 nM) was chosen from the T
3
dose-response curve considering
its greater inhibitory action on the Na+-K+-ATPase activity and to
observe the effect of graded doses (1 nM–2mM) of sodium ortho-
vanadate on this T
3
-induced inhibition. The data are represented as
mean± SEMof four separate experiments, taking six animals in each
group. The vertical bars denote SEM. Open circles indicate mean
values for a set of control incubations without T
3
. Filled triangles
indicate the results of a set of incubations with 10 nM T
3
.





mRNAs are highly expressed in the
cerebral cortex [40, 42, 43]. Activation of mGluR has been
shown to counteract 𝛽-adrenoceptor-mediated inhibition of
afterhyperpolarization in hippocampal neurons of the CA1
area. This has been suggested to be by mGluR-mediated
activation of protein kinase C, which inhibited adenylate
cyclase pathways [42, 43]. The physiological functions of
these mGluRs are still being clarified.Thus, T
3
action in adult
rat synaptosomalmembrane, ultimately to inhibit the effector
molecule Na+-K+-ATPase, might be mediated through Gs
stimulation. mGlu receptors may then have some regulatory
roles in counteracting T
3
-induced action.
Our observation showed that DB cAMP (a nonhydrolyz-
able formof cAMP and activator of cAMP-dependent protein
kinases) had a T
3
-like effect on Na+-K+-ATPase activity
(Figure 7). Furthermore, the in vitro addition of increased
doses of T
3
lowered the slope of the dose-response curve
for DB cAMP. Such a finding might be consistent with a
related mechanism for the effects of DB cAMP and T
3
, and
would not represent merely additive effects of two distinct
mechanisms. Our previous observations suggested that the
phosphorylation status of certain synaptosomal proteins
could be mediated via cAMP- and/or Ca2+-dependent path-
ways [12, 45]. A differential stoichiometry of phosphorylation
of the 𝛼-subunit of the Na+-K+-ATPase by protein kinase A
andprotein kinaseChas been shown to inhibit this enzymatic
activity in shark rectal gland, rat renal cortex, and basolateral
membrane vesicles from rat renal cortex [46].
The effect of the protein tyrosine phosphatase inhibitor
sodium orthovanadate [47] appeared to be additive to the
effect of T
3
, implying that there could be a separate mech-
anism of action of the two compounds (Figure 8). Since
vanadate is a blocker of tyrosine phosphatase activity, it also
could be speculated that T
3
-induced inhibition of Na+-K+-
ATPase activity is further suppressed by synergistic action by
vanadate via keeping the enzyme in its phosphorylated form,
causing inhibition of its activity. A point to note here is that
the 𝛼-subunit is the catalytic subunit and its phosphorylation
causes inhibition of this enzyme [46]. T
3
appears not to
have the inhibitory effect on Na+-K+-ATPase activity by an
influence on phosphatase activity.
5. Conclusion
Our results regarding T
3
action in relation to the inhibition
of synaptosomal Na+-K+-ATPase are consistent with a T
3
-
synaptosomalmembrane component binding site interaction
sensitive to the activation of Gi-protein. Such a membrane
binding component might interact with a Gs-protein, result-
ing in increased synthesis of cAMP. The membrane Na+-
K+-ATPase is involved in several aspects of physiological
processes. In the neuron, its inhibition is linked with neu-
rotransmitter release [46]. Hence, the present study provides




of the mechanism of action of TH in adult mammalian
brain has major implications in the higher mental functions
and in the regulation of several neuropsychiatric disorders
developed in thyroid dysfunctions in adult humans.
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